Owner Vertex Pharmaceuticals Incorporated

Inventors Garcia-Paredes, Cristina; Yip, Yvonne Yee Mai; Victor, Frantz; Collado, Ivan; Lamar, Jason Eric; Glass, John Irvin; Jin, Ling; Tebbe, Mark Joseph; Snyder, Nancy June; Wang, Q. May; Parker III, Raymond Samuel; Babine, Robert Edward; Chen, Shu Hui; Sun, Xicheng David; Guo, Deqi

Agent Spruson & Ferguson

Pub. Number AU-A-2012201015

Parent 2007240156

Filing date 21 February 2012

Wipo publication date 15 March 2012

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

A61K 31/13 (2006.01) - Amines, e.g. amantadine

A61K 31/437 (2006.01)

A61K 31/7052 (2006.01)

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/21 (2006.01) Medicinal preparations containing peptides - Interferons

A61K 38/55 (2006.01) Medicinal preparations containing peptides - Protease inhibitors

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 1/16 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 31/14 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 5/02 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/023 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/027 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/03 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 7/02 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 14/18 (2006.01) Peptides having more than 20 amino acids

C12N 7/06 (2006.01) Viruses, e.g. bacteriophages

C12N 9/99 (2006.01) Enzymes, e.g. ligases (6.) - Enzyme inactivation by chemical treatment